-
Dr. Junping Shi Leads China’s First Liver Biopsy-Based RCT (VENS Study) Confirming Vitamin E’s Safety & Efficacy in MASH
To explore this possibility, Dr. Junping Shi from the Affiliated Hospital of Hangzhou Normal University led a nationwide, multi-center, large-sample, randomized, double-blind, placebo-controlled clinical trial known as the VENS study…
-
At the EHA (European Hematology Association) congress, I witnessed the intellectual collision in the field of hematology. Scholars shared their research findings from the podium, with each presentation being a spark of knowledge and wisdom.
At the EHA (European Hematology Association) congress, I witnessed the intellectual collision in the field of hematology. Scholars shared their research findings from the podium, with each presentation being a…
-
At the European Hematology Association (EHA) congress , Professor Richard Van Wijk from the University Medical Center Utrecht delivered a captivating presentation titled “Activation of pyruvate kinase as a therapeutic option for rare hemolytic anemias.”
At the European Hematology Association (EHA) congress , Professor Richard Van Wijk from the University Medical Center Utrecht delivered a captivating presentation titled “Activation of pyruvate kinase as a therapeutic option for rare hemolytic anemias.” His insightful discussion on the potential of pyruvate kinase activation in treating these rare conditions has sparked significant interest among…
-
Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation presenting as pericardial effusion
The primary aim is to understand the characteristics, diagnosis, treatment, and prognosis of isolated extramedullary relapse (IEMR) in AML patients post-allo-HSCT, with a specific focus on cardiac involvement. A 35-year-old…
-
EHA China Spotlight | Professor Jing Pan: Previous-Transplant or New-Match Donor CD5 CAR-T Cells in Pediatric and Adult Relapsed/Refractory T-ALL: First-In-Human, Phase 1 Study
Study Overview Background Relapsed/refractory acute T-cell lymphoblastic leukemia (r/r T-ALL) lacks effective salvage therapies and has poor prognosis. Recently, CD7-targeted CAR-T cell therapy has shown efficacy in r/r T-ALL, but…
-
ASCO China Voice | Professor Jian Zhang: The First ADC Targeting Nectin-4, 9MW2821, Shows Promising Efficacy and Safety in Multiple Cancers
Study Overview Phase 1/2a Study Results of the First Nectin-4 Targeting ADC Drug 9MW2821 in Patients with Advanced Solid Tumors 9MW2821 is a monoclonal antibody-drug conjugate (ADC) that delivers monomethyl…
Connecting Medical Expertise through Media
